Phenotypic and genetic spectrum of epilepsy with myoclonic atonic seizures
Shan Tang,Laura Addis,Anna Smith,Simon D Topp,Manuela Pendziwiat,Davide Mei,Alasdair Parker,Shakti Agrawal,Elaine Hughes,Karine Lascelles,Ruth E Williams,Penny Fallon,Robert Robinson,Helen J Cross,Tammy Hedderly,Christin Eltze,Tim Kerr,Archana Desurkar,Nahin Hussain,Maria Kinali,Irene Bagnasco,Grace Vassallo,William Whitehouse,Sushma Goyal,Michael Absoud,EuroEPINOMICS-RES Consortium,Rikke S Møller,Ingo Helbig,Yvonne G Weber,Carla Marini,Renzo Guerrini,Michael A Simpson,Deb K Pal,Dana Craiu,Carol Davila,Alexandru Obregia,Peter De Jonghe,Anna-Elina Lehesjoki,Hiltrud Muhle,Bernd Neubauer,Kaja Selmer,Ulrich Stephani,Katalin Sterbova,Pasquale Striano,Tiina Talvik,Sarah von Spiczak,Sarah Weckhuysen,Hande Caglayan,Dorota Hoffman-Zacharska
DOI: https://doi.org/10.1111/epi.16508
IF: 6.74
Epilepsia
Abstract:Objective: We aimed to describe the extent of neurodevelopmental impairments and identify the genetic etiologies in a large cohort of patients with epilepsy with myoclonic atonic seizures (MAE). Methods: We deeply phenotyped MAE patients for epilepsy features, intellectual disability, autism spectrum disorder, and attention-deficit/hyperactivity disorder using standardized neuropsychological instruments. We performed exome analysis (whole exome sequencing) filtered on epilepsy and neuropsychiatric gene sets to identify genetic etiologies. Results: We analyzed 101 patients with MAE (70% male). The median age of seizure onset was 34 months (range = 6-72 months). The main seizure types were myoclonic atonic or atonic in 100%, generalized tonic-clonic in 72%, myoclonic in 69%, absence in 60%, and tonic seizures in 19% of patients. We observed intellectual disability in 62% of patients, with extremely low adaptive behavioral scores in 69%. In addition, 24% exhibited symptoms of autism and 37% exhibited attention-deficit/hyperactivity symptoms. We discovered pathogenic variants in 12 (14%) of 85 patients, including five previously published patients. These were pathogenic genetic variants in SYNGAP1 (n = 3), KIAA2022 (n = 2), and SLC6A1 (n = 2), as well as KCNA2, SCN2A, STX1B, KCNB1, and MECP2 (n = 1 each). We also identified three new candidate genes, ASH1L, CHD4, and SMARCA2 in one patient each. Significance: MAE is associated with significant neurodevelopmental impairment. MAE is genetically heterogeneous, and we identified a pathogenic genetic etiology in 14% of this cohort by exome analysis. These findings suggest that MAE is a manifestation of several etiologies rather than a discrete syndromic entity.